Evaluation of Enterococcus faecium EF137v on colorectal carcinogenesis.
- 2025
- Anais da Academia Brasileira de Ciencias 97(suppl 4)
- PubMed: 41417400
- DOI: 10.1590/0001-3765202520240896
Study Design
- Population
- Female Wistar rats with chemically induced colorectal cancer
- Methods
- Oral administration of Enterococcus faecium 137v at 10^10 CFU/ml with varying consumption periods; biochemical, histopathological, histochemical, immunohistochemical analyses for VEGF-A, IL-1β and TNF-α, morphometry and apoptosis
- Animal Study
Some probiotics bacterium such as Enterococcus faecium play an important role in the homeostasis of the gastrointestinal tract. It is therefore being a microorganism of interest in preventing the onset and progression of colorectal cancer (CRC). This study aimed to evaluate both the protective effect on colorectal carcinogenesis after the oral administration of Enterococcus faecium 137v - EF137v in an experimental model for CRC chemically induced by 1,2-dimethylhydrazine (DMH), and its hepatoprotective activity. Female Wistar rats were treated with DMH and received a dose of E. faecium at a concentration of 1010 CFU / ml, varying the consumption period per group. Biochemical, histopathological, histochemical, immunohistochemical analyzes for VEGF-A, IL-1β and TNF-α, morphometry and apoptosis were determined. The studyshowed that, after the administering of EF137v, the intestinal mucosa was preserved and an attenuated rate of apoptosis. Low glycogen levels were observed in the positive control group (G2) that received only DMH when compared to the others groups. Our findings suggest that EF137v has a preventive effect on preneoplasic lesion, reducing and/or inhibiting inflammation, in addition to which aberrant crypts form, and this especially contributes to preventing liver inflammation in na animal model.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|